Boston keratoprosthesis – Clinical outcomes with wider geographic use and expanding indications – A systematic review  by Al Arfaj, Khalid
Saudi Journal of Ophthalmology (2015) 29, 212–221Review ArticleBoston keratoprosthesis – Clinical outcomes with wider
geographic use and expanding indications – A systematic reviewPeer review under responsibility
of Saudi Ophthalmological Society,
King Saud University Production and hosting by Elsevier
Access this article onlin
www.saudiophthaljourn
www.sciencedirect.com
Received 11 October 2014; received in revised form 24 December 2014; accepted 2 February 2015; available online 10 February 2015.
Department of ophthalmology, Dammam University, Postal code 40033, King Fahad University Hospital, Alkhobar, Saudi Arabia
⇑ Tel.: +966 554488404.
e-mail address: kmarfaj@gmail.comKhalid Al Arfaj ⇑AbstractOver 2 decades of research, several design modifications, and improvements in post-operative management have made Boston
keratoprosthesis (B-KPro) a viable option for patients with corneal blindness for whom traditional keratoplasty procedure has a
very low probability of success. In this systematic review, we examined the indications, visual outcomes, complications and reten-
tion rate of the literature published in the past 10 years (2005–2014). While most of the studies report smaller datasets (typically
<50 eyes), some of the recent multicenter studies have reported large datasets (up to 300 eyes). Most of the literature is published
from the US; however, last few years have witnessed some papers reporting the successful use of B-Kpro from developing
countries or arid climatic conditions (such as the Kingdom of Saudi Arabia). Due to differences in the causes of corneal blindness
in different geographic regions, newer indications for B-Kpro are emerging (e.g. trachoma). Additionally, improving clinical
outcomes and increasing surgeon confidence have also expanded indications to include cases of unilateral visual impairment
and paediatric age. We observed that there is growing body of evidence of successful clinical use of B-KPro; however, financial
challenges, lack of trained surgeons, shortage of donor corneas must be overcome to improve accessibility of B-KPro.
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Corneal diseases are the leading cause of blindness world-
wide, second only to cataract.1–3 While corneal transplanta-
tion is highly successful in restoring sight,2 severely
diseased eyes with deep corneal vascularization, limbal stem
cell deficiency (LSCD), autoimmune diseases and chemical
injury etc. are prone to graft rejection.1,4 Keratoprosthesis
(KPro) seems to offer visual rehabilitation in such situations
where corneal transplantation has an extremely poor progno-
sis.1,4 As of today, Boston keratoprosthesis (B-KPro) is the
most commonly used KPro device worldwide. First case
series of patients who had undergone type 1 B-KPro was
reported in 1974, and the device was approved by the FDA
in 1992.5 Since its introduction, B-KPro has undergoneseveral design modifications, improving postoperative outcomes
and surgeon confidence.
A review of literature reveals that most of the papers have
been published from the US and reported smaller datasets
(typically <50 eyes).6–12 Recently, some of the papers from
the US have reported large multicenter data set of up to
300 eyes.13,14 With increasing accessibility of training
programmes, last 4 years have witnessed several papers
studying B-KPro implantation indications, complications
and outcomes being published from regions across the
world, particularly those from harsher climatic conditions
(e.g. Jordan and Saudi Arabia in the Middle East) and from
the developing countries (e.g. India, Nepal, Indonesia
etc.).5,12,15–17 Since the causes of corneal blindness necessitating
B-KPro implantation vary with different geographical loca-e:
al.com
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implantation (e.g. trachoma) are emerging. Similarly, the rate
of post-operative complications and their management may
vary with different geographical locations and climatic
conditions.
At this time point, it is worthwhile to conduct a review of
recent publications to examine the indications, visual
outcomes, complications and retention rate of the B-Kpro
literature published in the past 10 years, particularly of those
from harsher climatic conditions (such as Saudi Arabia).
Systematic review – methodology
We searched the PUBMED on December 18, 2014 (no
time limits) using relevant search terms such as Boston ker-
atoprosthesis, Boston KPro, B KPro etc. and found 230
related publications. Additionally, Google search engine
was searched for relevant literature. English language
studies (reviews, case series and case reports) were includ-
ed in the study. Results of English language publications
published between 2005 and 2014 and reporting outcomes
of 4 or more patients were reviewed and compared in
Table 1. In this review, we discuss about common
indications, postoperative outcomes including visual
acuity, retention rate, complications of B-KPro and their
management.
Keratoprosthesis: development history
The idea of replacing severely opacified cornea with artifi-
cial cornea (KPro) was first introduced by the French ophthal-
mologist, Guillaume Pellier de Quengsy way back in 1789.
After the first report of successful implantation of a quartz
crystal into the cornea was published in 1853,4,18 attempts
were made to refine KPro; however, high rate of failure with
tissue necrosis, leakage, infection and extrusion of the device
limited further developments. In the mean time, the first suc-
cessful human to human corneal graft by Zirm in 1906 shifted
the focus to keratoplasty and interest in KPro development
decreased.4 Gradually as the limitations of corneal transplan-
tation came to fore, there was a renewed interest to develop
KPro. KPro development received a major fillip after the high
bio-compatibility of polymethylmethacrylate (PMMA) was
learnt during World War II.4
Several different materials and designs have been
proposed for KPro; some of the KPros are totally synthetic
[e.g., B-KPro (also known as ‘Dohlman–Doane’ KPro) or
AlphaCor] and the others are totally biological (e.g., tissue
engineered cornea). Combined devices consisting of synthet-
ic as well as biological material (e.g., Osteo-odonto KPro) are
also available.19 Of these, US Food and Drug Administration
(FDA) approved KPros include B-KPro and AlphaCor.20 With
almost 200 peer-reviewed publications to date and with
>6000 implantations performed worldwide until 2011, B-
KPro is the most commonly used KPro in the United States
and the rest of the world.16,19,21,22
B-KPro – description
B-KPro is a double-plated PMMA device with a central
rigid optic that perforates the cornea. There are 2 variants
of the device. Type 1, the more common variant, is acollar button-shaped device with front plate (diameter
5.5–7.0 mm),20 a central optical stem, and a back plate
(available in 8.5 mm diameter adult size and 7.0 mm diameter
paediatric size),23 with 8/16 holes that facilitate the nutrition
and hydration of the corneal graft.24,25 The back plate of
the KPro is either screwed on to the stem to allow firm
apposition with the donor tissue or snapped onto the stem
with no rotating movement. A titanium locking ring is
snapped in place behind the back plate to prevent loosening
of the back plate. The graft prosthesis combination is then
sutured to the recipient’s trephined corneal opening as in
penetrating keratoplasty. Type 1 B-KPro is available in a sin-
gle standard pseudophakic power or customized aphakic
optic allowing a maximum visual field of 60.20
Type 2 B-KPro has a through-the-lid design with a 2 mm
anterior nub designed to penetrate through a tarsorrhaphy
and allow a visual field of 40.26 Type 2 is used in rare cases
of symblepharon, extreme dry eyes, and other clinical seque-
lae associated with the autoimmune and inflammatory dis-
ease category that includes Stevens Johnson Syndrome
(SJS) and Ocular Cicatricial Pemphigoid (OCP).B-KPro – introduction and improvements over time
B-KPro was originally developed at the Massachusetts
Eye and Ear Infirmary in the 1970s by Claes Dohlman as a
collar button design made of PMMA consisting of a front
plate, a stem, and a back plate.20,22,27 Since the FDA
approval in 1992 for marketing the device, several
design changes and improvements in the post-operative
management have helped reduce the postoperative compli-
cations and enhance the overall efficacy and safety of the
procedure.19,22,27,28
The first significant improvement included replacement of
the solid back plate with a back plate with holes. Addition of
16 round holes (1.17 mm diameter each) in the adult 8.5 mm
sized back plate and 8 (1.3 mm diameter each) in the
paediatric 7.0 mm sized back plate facilitated endothelial
and keratocyte nutrition.23,27,28 In addition, holes are also
hypothesized to play a role in allowing the aqueous to
replenish the fluid that has evaporated from the corneal
surface, thus keeping the cornea hydrated and preventing
dellen formation and dryness that could have lead to shrink-
age, with subsequent leakage.8
In 2003, titanium locking ring was introduced to prevent
any later intraocular unscrewing of the plates due to inade-
quate manual screwing.19,27,28 However, this system still
had several downfalls as manual screwing of the plates
required rotation of the back plate which caused extensive
damage to the posterior graft layers.23 In order to prevent
the carrier corneal graft from such damage and make the
device easy to use, a newer design with threadless stem
was introduced in 2007.19,23 Incidentally, it also decreased
the cost of manufacturing of the device as machining was
replaced by moulding.19
The latest attempt to improve B-KPro outcomes has
focused on exploring alternative materials. While PMMA is
a transparent, biologically inert material with long history of
safe intra-ocular use, several post-operative complications
have been linked to the thick PMMA back plate.28 Due to
titanium’s high resistance to corrosion, bio-inertness,
ductility, lightness and strength29 it can be easily machined
Table 1. Review of literature – summary of Indications, follow-up duration and outcomes of Boston keratoprosthesis.
Author/study Country/region Eyes Time at last
follow-up (FU)
CDVA
preoperative
CDVA postop Retention
rate
Secondary
KPro
Indications/
preoperative diagnosis
Complications
P20/50 P20/200 P20/50 P20/200
Al Arfaj 42 Saudi Arabia 16 >4 yrs 0% 0% 0% 69% 81.3% 50% Trachoma (34.25%) RPMc (50%)
Decompensated cornea post
phacoemulsification (18.75%)
Worsened Glaucoma (18.8%)
Vitreous haemorrhage (12.5%)
Lekhanont 45 Thailand 42 4–5 yrs 0% 0% NA 43% 80.9% 59.5% Corneal oedema (21.4%) Glaucoma/Elevated IOP (80.9%)
Chemical injury (19.1%) RPM (52.4%)
Corneal dystrophies (19.1%) Corneal melt (23.8%)
Srikumaran 46 USA 139 6 wks–8.7 yrs NA 10.8% NA 70% 67% 73% Bullous keratopathy (35.3%) RPM (49.7%)
Ocular Surface Disease (23%) Glaucoma/Elevated IOP (36.2%)
Congenital Corneal
abnormalities (12.9%)
Sterile corneal necrosis (19.5%)
De Oliveira 43 Brazil 30 1–55 months 0% 0% NA 80% 93.3% 53.3% Chemical injury (33.33%) Worsened Glaucoma (43%)
SJS (13.33%) RPM (26.66%)
Corneal melt (20%)
Phillips 47 USA 9 29–60 months 0% 11.11% 44.4% 22.2% 77.8% 88.9% Chemical/Thermal burns (100%) Cyclitic membrane/RPM (22.2%)
Microbial keratitis (22.2%)
Sterile corneal ulceration (22.2%)
Hassanaly 48 Canada 26 4–50 months 0% 0% 0% 54% 77% 27% Aniridia (100%) Glaucoma (88%)
RPM (58%)
Vitritis (26.1%)
Brown 49 USA 9 22–63 months 0% 22.2% 11.1%a 66.7% 66.7% 88.9% Herpes simplex virus (55.6%) Epiretinal membrane (66.7%)
Herpes zoster virus (44.4%) RPM (44.4%)
Microbial keratitis (33.3%)
de la Paz 22 Europe 67 3 yrs NA NA NA NA 78% 83%b Autoimmune (24%) RPM (34%)
Chemical/Thermal burns (18%) New/worsened Glaucoma (24%)
Leukoma post Infectious Keratitis
(10.5%)
Retinal/choroidal detachment
(19%)
Endophthalmitis (13%)
Jasinskas 17 Lithuania 5 3–5 yrs 0% 0% 60% 100% 100% 60% RPM (40%)
Chemical injury (20%) Elevated IOPd (100%)
Thermal injury (20%) Secondary cataract formation
(40%)
Ciolino 50 USA 300 1 wk–>6.1 yrs NA NA NA NA 93% 86.2% Bullous keratopathy (18.3%) RPM (1%)e
Autoimmune (10.3%) Infectious keratitis (6.3%)e
Chemical injury (10.3%) Sterile corneal necrosis (1.7%)e
Shihadeh 5 Jordan 20 3–36 months 0% 0% 25% 65% 90% 95% Corneal vascularization (40%) RPM (45%)
Keratoconus (20%) New/worsened glaucoma (20%)
Infectious keratitis (10%)
Al Arfaj 15 Saudi Arabia 4 6–14 months 0% 0% 25% 100% 75% 25% Trachoma (50%) PEDf (25%)
Chemical injury (25%) Prosthesis edge melts (25%)
Rudinsky 32 USA 265 146 eyes
(P1 yr FU),
Bullous keratopathy (15.5%) RPM (31.7%)
87 eyes
(P2 yrs FU)
NA NA NA NA NA 85.4% Chemical injury (9.1%)
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Aldave 16 Armenia, India,
Indonesia, Nepal,
Philippines, Russia,
Saudi Arabia
107 <1.0–48 months 0% 1% 18%g 41%g 81% 44% Chemical injury (27%) RPM (27%)
SJSh (8%) Sterile Corneal Necrosis (18%)
Elevated IOP (14%)
USA 98 <1.0–84 months 0% 6% 16%i 29%i 80% 64% Repeat KPro (12%) RPM (46%)
Chemical injury (7%) PED (34%)
Elevated IOP (19%)
Patel 41 USA 58 3–47 months NA 2% NA 43% 78% 81% Infectious keratitis (19 %) RPM (50%)
LSCDj/Bullous keratopathy (17%) Elevated IOP (25.9%)
Prosthetic melt (25%)
Greiner 11 USA 40 P1 year 0% 5% 48% 50% 80% 47.5% Chemical injury (25%) RPM (55%)
Aniridia (12.5%) Elevated IOP (40%)
Glaucoma: New (27.5%)
Worsened (22.5%)
Robert 12 Canada 47 3–18.5 months NA P6% P11% NA 100% 57% Aniridia (34%) Elevated IOP (51%)
Bullous keratopathy (11%) RPM (26%)
New/worsened glaucoma (21%)
Sejpal
(LSCD)35
USA 23 0.5–58.6
months
0% 4% 30%i 30%i 74% NA LSCD (100%) PED (56.5%)
Chemical injury (30.4%) Sterile corneal necrosis (30.4%)
SJS (26.1%) RPM (26.1%)
Sejpal (non-
LSCD)35
USA 56 0.5–
58.6 months
0% 9% 5%i 20%i 82% NA NA RPM (46.4%)
PED (23.2%)
Elevated IOP (17.9%)
Verdejo-
Gomez 51
Spain 12 23 months
(mean FU)
0% 0% 8% 17% 100% 92% Herpes keratitis (8%) Corneal thinning (33%)
Glaucoma progression (8%)
Chew 10 USA 37 6–28 months 0% 14% 43% 81% 100% in
type 1k
59% Bullous keratopathy (42%) RPM (67%)
Aniridia (11%)
Elevated IOP (39%)
Glaucoma (14%)
Bradley 9 USA 30 1 yr 0% 13% >23% 75% 83.30% 87% Chemical injury (10%) RPM (43%)
SJS (3%)
Elevated IOP (27%)
Infectious keratitis (17%)
Corneal Melt (17%)
Aldave 34 USA 50 4 yrs 0% 10% NA 100% 84% 84% LSCD (28%) RPM (44%)
Chemical injury (10%) PED (38%)
Elevated IOP (18%)
Sayegh 8 USA 16 10.2 months–
5.6 yrs
0% 0% 31% 50% NA NA SJS (100%) RPM (56.5%)
Skin retraction (Type 2) (25%)
Retinal detachment (12.5%)
Akpek 7 USA 16 2–85 months 0% 0% 0% 63% 100% 68.75% Aniridia (100%) RPM (12.5%)
Choroidal detachment (12.5%)
(continued on next page)
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216 K. Al Arfajinto thin, flexible, larger diameter plates (which are resilient
to stress),6,11 potentially reducing the incidence of post
operative complications such as anterior iris synechiae and
angle closure glaucoma,27,30 particularly in uveitis or sterile
vitritis cases. Todani et al. investigated the clinical outcomes
of combining the transparent PMMA stem and front plate
with titanium back plate and reported the decline in rate of
retroprosthetic membrane (RPM) formation from 46.1% in
eyes implanted with threaded PMMA to 31.2% with thread-
less PMMA to 13% in threadless titanium backplates.31Clinical outcomes
Type 1 B-KPro
Indications
The B-KPro is indicated for patients with refractory corneal
blindness and having extremely poor prognosis for penetrat-
ing keratoplasty. A review of literature revealed that sec-
ondary keratoprosthetic implantation (KPro implantation
attempted after failed corneal graft) accounted for majority
of the cases, as high as 95% of the procedures in a study from
Jordan, followed by 88% and 87% in two studies from the
United States (Table 1).5,6,9 The two large data set multicen-
ter studies involving up to 300 eyes also reported failed cor-
neal graft to be the most common indication (85–86%).32,33
Literature review also seems to suggest that indication of
primary B-KPro implantation (KPro implantation performed
without first attempting keratoplasty) included eyes with sev-
ere ocular surface damage due to chemical or thermal injury
(percentages varying from 7% to 30.4% in different studies)
(Table 1)9,11,15–17,31–35 or autoimmune diseases such as SJS
(2.5–100%)8–11,16,34,35 or congenital anomalies such as aniri-
dia (1–100%).12,17,23,34–37 While bullous keratopathy and anir-
idia were reported commonly in the studies from the US and
Canada, post-trachomatous scarring15 was the most common
indication from Saudi Arabia (Fig. 1) and chemical injury was
the common indication internationally.7,12,13,16,17,20,23,34,38
Thus the indications for B-Kpro from different geographical
regions vary due to differences in the causes of corneal blind-
ness. Further, advances in post-operative outcomes, reduc-
ing rate of complications,27 and increasing surgeon
confidence have also expanded indications and reduced con-
tra-indications. Unilateral visual impairment, which was once
considered a strong relative contraindication due to high
risks associated with KPro implantation, is no longer consid-
ered so, as some studies have reported good visual out-
comes with restoration of binocularity.34,36,37 B-KPro has
also been successfully implanted in paediatric eyes.39,40 Since
traditional penetrating keratoplasty in children has poor
prognosis due to their robust immune response, typically
resulting in prolonged recovery time and neovascularization
extending into the visual axis successful B-KPro implantation
may prevent stimulus deprivation amblyopia.40 It is being
hypothesized that, after successfully preventing amblyopia,
keratoprosthesis may be exchanged for a traditional corneal
transplant later in life.39
Visual outcomes
Most of the studies reported pre-operative visual acuity of
worse than 20/200 in majority of the eyes. Post-operatively,
visual acuity improved significantly with majority of the stud-
Figure 1. (A) Pre-operative clinical photograph of the right eye of a patient with post-trachomatous corneal scarring showing deep vascularization in all 4
quadrants. (B) Post-operative clinical photograph of patient 6 months after B-KPro implantation.
Boston keratoprosthesis: Review of clinical outcomes and expanding indications 217ies reporting more than 50% of the eyes achieving CDVA of
20/200 or better (Table 1). While several studies reported
achieving CDVA of 20/50 or better in at least some of the
eyes 4 papers reported achieving CDVA of 20/50 or better
in 43–60% of their dataset.10,11,17,41 Visual acuity in case ser-
ies from arid climatic conditions of Saudi Arabia and Jordan
also reported good visual outcomes with 65–100% of the
eyes achieving CDVA of 20/200 or better and 0–25% of the
eyes achieving visual acuity of 20/50 or better5,15,42 which
are comparable to those from the US (with 20–81% of the
eyes achieving CDVA of 20/200 or better and 0–48% of the
eyes achieving CDVA of 20/50 or better).Retention rate
Overall, between 74% and 100% of B-KPro were reported
as retained at the last follow-up (range 1 week to 85 months,
Table 1). The longest reported retention time (of at least one
patient in a 16 cases report by Akpek et al.) is 85 months.7
Retention rate of 100% has been reported in 5 publications
containing data of 5–47 eyes (3 from the US, 1 from Canada
and 1 from Lithuania).6,7,10,12,17 Even in the studies reporting
larger dataset (136–300 eyes), retention rate of 93–95% is
obtained.31,38 Case series from Saudi Arabia and Jordan have
also reported good retention rates (75–100%)5,15,42; it is
important to note that despite the arid climate of this region,
which contributes to the ocular surface dryness, the retention
rate reported in this study is consistent with the reports from
other parts of the world.
The expected outcomes seemed to be influenced by the
primary indications. Apparently, best results were observed
in non-cicatrizing conditions and preoperative conditions
such as autoimmune diseases, chemical injury, LSCD, deep
corneal vascularization were found to be associated with
studies reporting lower retention rates.11,15,16,22,34,35 Similar-
ly, complications such as persistent epithelial defect (PED),
corneal necrosis and endophthalmitis seemed to be more
common in case series reporting comparatively lower reten-
tion rates.15,16,22,35
While elevated intraocular pressure (IOP) (14–100% eyes)
and glaucoma (2–43% eyes) were a common complication,
it did not seem to affect the retention rates.5,12,17,43,44 As
such, RPM was the most commonly reported complication
(affecting between 12% and 67% eyes). Other common
complications included PED (23–56.5%), infectious keratitis
(6.3–17%), sterile corneal necrosis, Retinal/choroidaldetachment, prosthetic melt, endophthalmitis, secondary
cataract and sterile vitritis (Table 1).
Type 2 B-KPro
There is limited literature on the outcomes of type 2
B-KPro, a total of 11 eyes compared to approximately 1400
eyes of type 1 B-KPro. Sayegh et al. reported data of 16
B-KPro implantations in SJS affected eyes out of which 10
had undergone type 2.39 Complications were reported for
all the 16 eyes; separate statistics are not available for B-KPro
type 2. Chew et al. reported data of 36 type 1 B-KPro and
one type 2 B-KPro for a case of OCP while retention rate
was 100% for type 1 (6–28 months follow-up), type 2 got
extruded after 9 months of follow-up.37
Post-operative complications – prevention and
therapeutics
Over the decades, improvements in the postoperative
management have contributed to the improvement of KPro’s
clinical outcomes.
Ocular surface dryness
Managing ocular surface dryness is one of the most sig-
nificant challenges in the post-operative care of B-KPro as it
may cause dellen formation and ulceration.27,28 Bandage
contact lenses have been found to significantly improve ocu-
lar surface health and stability, reducing the incidence of dry-
ness associated complications. In addition to its protective
and therapeutic roles, bandage contact lens after KPro sur-
gery also improves cosmesis and allows refractive adjust-
ments (it is possible to customize the bandage contact
lenses to offer refractive correction).52 While bandage con-
tact lenses are advantageous in improving ocular surface
health, it is important to regularly clean and if needed replace
them, so that they do not serve as foci of infection.53
Endophthalmitis
Due to the very nature of the procedure, in which a non-
biointegrating material replaces the entire thickness of the
central cornea as eye’s outer most layer, B-KPro carries a long
term risk of infection. Literature review revealed endoph-
thalmitis prevalence rate of 0-13% in patients implanted with
218 K. Al ArfajB-KPro.5,9–11,16,22,33,41,53 In order to prevent potentially sight
threatening post-operative infections such as endophthalmi-
tis,53 the use of prophylactic antibiotics is recommended. In
particular, the use of vancomycin has reduced the incidence
of infectious endophthalmitis in autoimmune patients as
well.27,28 Concurrent use of vancomycin or chloramphenicol
along with fluoroquinolones is recommended in high risk
patients after B-KPro as preventive measures.53–55 However,
vancomycin must be specially prepared and chloramphenicol
is not commercially available in some countries for e.g., the
US.55 While the chronic use of low-dose antibiotics may help
decrease the risk of infection, it may, to the contrary, increase
the risk of inducing resistance among ocular flora. There are
suggestions that increase in dosage from 2 times to 4 times
per day may possibly prevent such development of
resistance.10
Patients with autoimmune disease and chemical burns are
more vulnerable to endophthalmitis development.53 Regular
cleaning and replacement of therapeutic contact lens are also
recommended to remove the bulk of infecting colonies.53Retroprosthetic membrane
RPM is one of the most common complications (affecting
12–67% of eyes) after B-KPro.10,11,16,17,22,31,32 According to a
recent multicenter study, B-KPro implantation in eyes with
corneal blindness due to infectious keratitis and aniridia is
at the highest risk of RPM development.33 In contrast, chemi-
cal injury seems to be protective against RPM development
with only one-third of these patients developing RPM after
a longer time period.32 In most cases, Nd:YAG laser mem-
branectomy can effectively treat RPM before it becomes
too thick and vascularized.20,27,28Elevated IOP and glaucoma
One of the most difficult complications to be managed
after KPro is glaucoma.13 As such, eyes that need KPro
implantation are severely diseased with most of them either
already having glaucoma or being highly vulnerable to
developing glaucoma.56 A review of literature reveals that
after B-KPro implantation, incidence of elevated IOP is
14–100%9–11,16,31,34,35,41 and that of new or worsened
glaucoma is 2–43% of the eyes in the US as well as Middle
East region.5,7–12,16,22,34,43,44
A recent publication reporting anterior segment OCT find-
ings of the B-KPro implanted eyes revealed that early ana-
tomic changes related to glaucoma progression (anatomic
angle narrowing and synechiae progression) were present
in almost all eyes (including eyes with no previous history of
glaucoma or increased IOP), suggesting that there is a long
term risk of almost all eyes progressing to glaucoma.44
Therefore, all B-KPro implanted patients should be followed
up closely, so as to diagnose and manage raised IOL early
on14; however, IOP monitoring in these patients remains
challenging as there are no reliable tools to assess IOP in
B-KPro implanted eyes and therefore clinician’s reliance on
the subjective digital palpation to monitor IOP.13,57 IOP can
be controlled by surgical placement of glaucoma drainage
device, but the procedure itself may cause several
complications.13Endoscopic or transscleral diode cyclophotocoagulation
or pars plana tube insertion may be attempted when previ-
ously placed glaucoma drainage devices are not adequately
functioning.57 Pars plana tube insertion with concomitant
pars plana vitrectomy may be a viable alternative treatment
that can avoid occlusion secondary to anterior segment
crowding or to vitreous and iris plugging. In addition, the vit-
rectomy offers the ability to clear any vitreous opacities or
RPM that may be obstructing vision.57
Corneal melt
The incidence of corneal melt as reported in the literature
is also high (1.5–17%).7–9,11,31,58 Although keratoprosthesis
design with 859 (and now 16) backplate holes has lowered
the incidence of corneal melt from 51% to 10%, the risk of
developing corneal melt in high-risk patients can be further
minimized by using bandage contact lens which improves
corneal hydration and thus prevents dellen formation and
melting.10 The management of corneal melt is usually done
by optimization of the tear film (with artificial tears and punc-
tual occlusion), resuturing, cyanoacrylate glue application
and use of anti-collagenolytic agents, such as topical
medroxyprogesterone and oral tetracyclines.60,61 In addition,
surgical measures such as tutoplast patch graft, conjunctival
flap, buccal mucosal graft, lateral tarsorrhaphy, donor cor-
neal lamellar graft or crescentic amniotic membrane grafting
can be performed in severe cases.61 Eyes with corneal melt
and concomitant active autoimmune disease may benefit
from the administration of systemic immunosuppressives. In
refractory cases, the device may be explanted and replaced
with another keratoprosthesis or managed with regraft.61
Vitreoretinal diseases
Vitreoretinal complications after B-KPro implantation,
specifically retinal detachment have been reported in
5–19% of the eyes.7,8,12,16,22,31,34,35,41 Such complications
usually require surgical management by pars plana vitrecto-
my, which reportedly can be performed successfully in
B-KPro implanted eyes. While such vitreo-retinal procedures
have yielded good anatomical outcomes, visual recovery has
not been commensurate, typically offering little improvement
in visual acuity.62,63
Improving outcomes – future developments
Literature published to date indicates promising results of
B-KPro implantation; however, there are several facets of B-
KPro design, implantation and post-operative care that need
continued innovation and development.
IOP measurement devices
Prevention of glaucoma after B-KPro surgery is a major
priority at the time of KPro evaluation and during postop-
erative follow-up. Due to the rigidity of the large B-KPro back
plate in B-KPro–implanted patients (with preoperative glau-
coma), it is difficult to accurately measure IOP by means of
standard tonometers.56 Therefore, there is a need to develop
innovative IOP measurement devices. Telemetric IOP
measurement is one such technique, which allows monitoring
of IOP in patients with keratoprosthesis whose IOP cannot be
Boston keratoprosthesis: Review of clinical outcomes and expanding indications 219measured by current methods. A recent experimental study
of telemetric IOP records used a wireless transducer implant-
ed in rabbits after extracapsular lens extraction demonstrat-
ing concordance with direct manometry measures.64
Further studies are necessary, however, to validate its use
and safety in human eyes.Retro-backplate membrane thickness and risk of melt
While the recent B-KPro model having 16 backplate holes
has substantially reduced the risk of corneal melt, it still
occurs in 1.4–17% of the surgeries.11,31,34 It has been
postulated that the formation of a retro-backplate membrane
in B-KPro patients predisposes patients to melt (sterile kera-
tolysis) because of the resultant occlusion of backplate holes
and impedance of nutritional support from the aqueous
humour.58 However, the newer large diameter titanium
backplate B-KPro design may offer greater protection from
RPM formation than the older PMMA backplate model.29
Further studies with the new titanium backplate B-KPro
may evaluate the incidence of RPM formation and the role
they play in melt pathogenesis.58Prevention of infectious keratitis and endophthalmitis
after KPro implantation
Infectious keratitis, corneal melts and endophthalmitis are
inter-related problems that may result in devastating conse-
quences after KPro surgery.65 While the management of
endophthalmitis after KPro implantation has improved,
post-KPro endophthalmitis continues to have higher inci-
dence, early onset and extremely poor visual outcome com-
pared with other intraocular surgeries.66 Since the aetiology
of post-KPro endophthalmitis may include both bacterial
and fungal infections,66 therapeutic dosing of topical antibi-
otics and antifungal agents, rather than the chronic low-dose
prophylaxis antibiotics currently used after KPro surgery, may
possibly prevent the development of resistant organisms.53,54
Alternatively, the use of antibiotic-coated prostheses or
antibiotic-secreting contact lenses has been proposed and
is under active investigation.60,67 A recent publication
explored the use of high-fluence collagen crosslinking (CXL)
as a means of achieving increased corneal rigidity and
reduced enzymatic digestion in the vehicle cornea of 11 B-
KPro eyes and reported no corneal melts and/or infection
over a mean follow up of 7.5 years (range 1–9 years)68; the
results seem very promising and future studies may validate
the reproducibility of outcomes under different clinical
settings.Keratoprosthesis in autoimmune diseases
The KPro surgery has enjoyed high success rates, par-
ticularly in the category of nonautoimmune patients; howev-
er, in patients with inflammatory autoimmune diseases,60
continued innovations and clinical trials are needed. Studies
are needed to assess the clinical importance of commensal
organisms on the ocular surface of KPro patients, and for
potential inflammatory responses to the materials contained
in the KPro.60 With improved understanding of the underly-
ing disease mechanisms in autoimmune disorders, in futuremore directed treatments for patients needing KPro for
autoimmune corneal blindness may be achieved.
Although, patients with autoimmune diseases such as SJS
usually have a poor long term prognosis of Kpro implanta-
tion, the retention rate and visual outcomes of the prosthesis
implantation can be improved by regular systemic autoim-
mune therapy such as monthly infliximab infusions.69 Further
studies are required to assess the effect of systemic autoim-
mune therapy on prosthesis retention and visual outcomes in
other autoimmune diseases.Enhancing accessibility
While continued research and innovation are indispens-
able to improve B-KPro’s design and material and decrease
associated complications, efforts must also be made to
enhance its accessibility. Majority of people with corneal
blindness needing surgical rehabilitation live in the develop-
ing countries where training programmes in B-KPro implanta-
tion are not available, donor corneal tissue is scarce and
recipients cannot afford the cost of KPro surgery and post-
operative care.1,21 It is, therefore, important that the formal
training programmes in B-KPro implantation, that are cur-
rently offered in only a few countries, be made available to
the surgeons all over the world; it may increase the accessi-
bility of KPro to a lot more patients in need.1 Additionally,
there is a need to find alternative carrier tissue that must
be inexpensive, readily available, and safe so that scarcity
of corneal tissue does not limit the utility of B-KPro. Available
data on the use of cryo-preserved and gamma-irradiated car-
rier corneas seem promising; visual acuity outcomes, inci-
dence of complications, and retention percentage of the
KPro implantations with preserved carrier corneas have been
found to be comparable to those with fresh carrier
corneas.70,71 While B-KPro is already being made available
at subsidized rates in developing countries, increasing use
of B-KPro may facilitate economy of scale in production,
potentially further decreasing costs.Funding sources
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